Pityriasis Rosea

Detailed Overview

The condition is harmless but often alarming to patients due to the sudden widespread rash. It is widely considered to be a viral exanthem, strongly linked to systemic reactivation of Human Herpesvirus 6 (HHV-6) and HHV-7. The rash typically lasts 6-8 weeks but can persist for months. It leaves no scars, though post-inflammatory hyperpigmentation or hypopigmentation can occur, particularly in darker skin tones. It is not considered highly contagious.

Epidemiology & Demographics

Common worldwide. Most frequently affects children, adolescents, and young adults (ages 10-35). Slight female predominance. Incidence peaks in the spring and autumn months.

Etiological Mechanism

The exact cause is not definitively proven, but robust evidence points to the endogenous reactivation of HHV-6 and HHV-7. Unlike primary infection (which causes roseola in infants), this is a reactivation event. Certain drugs (e.g., ACE inhibitors, metronidazole, isotretinoin, gold, biologics) can cause a pityriasis rosea-like drug eruption.

Primary Causes

Viral reactivation (HHV-6/7). Immune response to the virus in the skin leads to the characteristic scaly plaques.

• Age: Being between 10 and 35 years old.
• Recent Upper Respiratory Infection: Often preceded by mild prodromal viral symptoms (sore throat, fatigue) in up to 69% of patients.

Systemic viral reactivation leads to viremia. The virus targets the skin, inducing an inflammatory response. Histologically, there is focal parakeratosis, absence of the granular layer, and spongiosis in the epidermis, with a perivascular lymphocytic infiltrate in the superficial dermis and extravasated red blood cells. The herald patch represents the initial site of intense local inflammation, while the secondary rash represents a generalized immune-mediated delayed hypersensitivity response to the circulating virus.

Characteristic Clinical Presentation

• Herald Patch: A single, sharply defined, 2-10 cm oval erythematous plaque with a scaly border, usually on the trunk or proximal extremities.
• Secondary Rash: Multiple smaller (0.5-2 cm) scaly plaques appearing 1-2 weeks later, predominantly on the trunk and proximal limbs, sparing the face, palms, and soles.
• Pruritus: Mild to severe itching in about 50% of patients, worsened by sweating or hot showers.
• Prodrome: Mild fever, headache, or malaise preceding the rash (occurs in a minority of patients).

Physical Examination Signs

• 'Collarette of scale' - fine scale attached at the periphery of the lesion with the free edge pointing inward.
• 'Christmas tree' distribution - oval lesions align their long axes parallel to the lines of cleavage (Langer's lines) on the back.
• Sparing of sun-exposed areas (face, distal extremities) in the classic presentation.

• Post-inflammatory Hyperpigmentation: Dark spots lasting months after the rash clears, significant in Fitzpatrick skin types III-VI.
• Pregnancy Complications: If PR develops in the first 15 weeks of pregnancy, there is a reported increased risk of miscarriage or premature delivery.

Diagnostic Criteria & Guidelines

Diagnosis is entirely clinical, based on the characteristic history (herald patch followed by secondary eruption) and morphology (collarette of scale, Christmas tree pattern). No biopsy is needed for classic cases.

Differential Diagnosis

• Secondary Syphilis (crucial to rule out; syphilis usually involves palms and soles)
• Tinea Corporis (ringworm; usually fewer lesions, KOH positive)
• Guttate Psoriasis (thicker silvery scale, history of strep throat)
• Nummular Eczema

Laboratory Tests & Biomarkers

• RPR or VDRL: Should be negative (checked to rule out secondary syphilis, especially if palms/soles are involved or patient is sexually active).
• KOH Preparation: Negative for hyphae (rules out tinea corporis).

Imaging Modalities & Findings

• None:

• Prodromal
  Nonspecific viral symptoms (headache, malaise) before the rash.
• Herald Patch Stage
  Appearance of the initial large primary plaque.
• Eruptive Stage
  Dissemination of the secondary rash over 1-2 weeks.
• Convalescent Stage
  Spontaneous resolution over 4-8 weeks, leaving post-inflammatory pigment changes.

Second-Line & Adjunctive Therapy

For severe, extensive, or intensely pruritic cases: Oral Acyclovir (800 mg 5 times daily for 1 week) started early in the disease course has been shown to hasten resolution. Narrowband UVB phototherapy can also accelerate clearing but may increase the risk of post-inflammatory hyperpigmentation.

Surgical & Procedural Management

None.

Recommended Lifestyle Changes

Patient Counseling & Advice

Reassure the patient that the rash is not contagious, not a sign of poor hygiene, and not a dangerous infection. Inform them that it will take 6-8 weeks to go away completely. Warn them about the possibility of temporary dark spots remaining after the rash clears, which will fade over months.

Follow-Up & Monitoring Schedule

No routine follow-up is necessary unless symptoms are refractory, the rash persists beyond 3 months (prompting biopsy to rule out parapsoriasis or cutaneous T-cell lymphoma), or if palm/sole lesions appear.

Preventive Strategies

No known preventive measures.

Excellent. It is a benign, self-limited condition with permanent immunity; recurrence is rare (occurring in about 2% of patients).